REGISTER
Plozasiran Opens China's Rare Lipid RNA Market
China's approval of plozasiran for familial chylomicronemia syndrome is a milestone for both rare-lipid medicine and RNA therapeutics. The product combines a mechanistically precise APOC3-silencing strategy with strong triglyceride lowering, a reduced pancreatitis burden and a dosing schedule that can materially change long-term disease management.

Milestone

The milestone is full NMPA approval of plozasiran injection for adults with familial chylomicronemia syndrome, to be used on top of dietary control for triglyceride reduction. The product is the first siRNA directed against APOC3 mRNA and marks the end of the "no approved drug" era for FCS in China. For a disease long defined by strict dietary burden, recurrent pancreatitis risk and limited pharmacologic options, that is a clinically meaningful regulatory advance rather than a niche commercial footnote.

Disease context and unmet need

FCS is rare, severe and biologically unforgiving. The disease affects roughly 1 per million people and is commonly driven by loss-of-function mutations affecting lipoprotein metabolism genes such as LPL, GPIHBP1, APOC2, APOA5 and LMF1. Patients often present with fasting triglycerides above 880 mg/dL and remain at risk of life-threatening acute pancreatitis, along with hepatic steatosis, diabetes and other complications. Prior to plozasiran, Chinese patients had no approved disease-specific drug.

Mechanistic rationale

Plozasiran is a liver-targeted siRNA that silences APOC3 mRNA. The biology is elegant and clinically relevant. APOC3 is a key regulator of triglyceride-rich lipoprotein metabolism, in part by inhibiting lipoprotein lipase-mediated clearance and reducing hepatic uptake of remnants. Lowering APOC3 therefore addresses a core bottleneck in triglyceride handling. The therapy is not a best-in-class reformulation of older lipid management; it is a mechanistically targeted intervention aimed directly at a critical node in severe chylomicronemia.

Clinical evidence

China's approval was supported by global studies including the pivotal phase III PALISADE trial, plus local phase I evidence. PALISADE was randomized, double-blind and placebo controlled, with placebo-adjusted median triglyceride change at month 10 as the primary endpoint. Median triglyceride reductions reached 80% and 78% for the 25 mg and 50 mg plozasiran groups, respectively, with all key secondary endpoints also met. The broader clinical package also emphasized reduced acute pancreatitis risk and a quarterly dosing schedule, framing the drug as both biochemically potent and practically manageable.

Safety and risk-benefit balance

No newly emergent severe safety signal has defined the program so far, and the drug appears tolerable enough to support chronic quarterly administration. In an ultra-rare disease, the risk-benefit threshold is shaped by pancreatitis prevention and long-term adherence. A therapy that lowers triglycerides by roughly 80% with four doses per year has a compelling practical profile, provided safety remains stable in broader post-approval use. That is especially relevant in FCS, where patients often endure years of management strategies that are burdensome but only partially effective.

Strategic and competitive positioning

The approval also has broader strategic importance for Sanofi and for the RNA field in China. Sanofi paid $395 million to acquire Greater China rights from Viviazhen, signaling that large multinational companies now view specialized RNA assets as commercially important even in rare-disease categories. More broadly, plozasiran helps extend RNA therapeutics into chronic metabolic disease, complementing the class expansion already seen with Leqvio and olezarsen. Within treatment algorithms, plozasiran is likely to become the anchor therapy for genetically confirmed FCS rather than a salvage option.

Outlook

The remaining questions are predictable: how broadly patients can be identified, whether pancreatitis-event reduction continues to track with the biochemical effect in real-world practice, and how reimbursement affects uptake in a tiny but high-need population. Yet the overall conclusion is straightforward. Plozasiran is not just another imported rare-disease product entering China. It is a proof point that mechanistically sharp RNA medicines can solve previously neglected metabolic problems with both clinical depth and manageable dosing. For FCS patients, that is transformative. For the industry, it is another sign that RNA therapeutics are steadily becoming standard tools in chronic-disease medicine.

0
0
Loading